Beata Lecka-Czernik1, Sudipta Baroi2, Lance A Stechschulte2, Amit Sopan Chougule2. 1. Department of Orthopaedic Research, Physiology and Pharmacology, Center for Diabetes and Endocrine Research, University of Toledo Health Sciences Campus, 3000 Arlington Avenue, Toledo, OH, 43614, USA. beata.leckaczernik@utoledo.edu. 2. Department of Orthopaedic Research, Physiology and Pharmacology, Center for Diabetes and Endocrine Research, University of Toledo Health Sciences Campus, 3000 Arlington Avenue, Toledo, OH, 43614, USA.
Abstract
PURPOSE OF REVIEW: The goal of this review is to summarize recent findings on marrow adipose tissue (MAT) function and to discuss the possibility of targeting MAT for therapeutic purposes. RECENT FINDINGS: MAT is characterized with high heterogeneity which may suggest both that marrow adipocytes originate from multiple different progenitors and/or their phenotype is determined by skeletal location and environmental cues. Close relationship to osteoblasts and heterogeneity suggests that MAT consists of cells representing spectrum of phenotypes ranging from lipid-filled adipocytes to pre-osteoblasts. We propose a term of adiposteoblast for describing phenotypic spectrum of MAT. Manipulating with MAT activity in diseases where impairment in energy metabolism correlates with bone functional deficit, such as aging and diabetes, may be beneficial for both. Paracrine activities of MAT might be considered for treatment of bone diseases. MAT has unrecognized potential, either beneficial or detrimental, to regulate bone homeostasis in physiological and pathological conditions. More research is required to harness this potential for therapeutic purposes.
PURPOSE OF REVIEW: The goal of this review is to summarize recent findings on marrow adipose tissue (MAT) function and to discuss the possibility of targeting MAT for therapeutic purposes. RECENT FINDINGS:MAT is characterized with high heterogeneity which may suggest both that marrow adipocytes originate from multiple different progenitors and/or their phenotype is determined by skeletal location and environmental cues. Close relationship to osteoblasts and heterogeneity suggests that MAT consists of cells representing spectrum of phenotypes ranging from lipid-filled adipocytes to pre-osteoblasts. We propose a term of adiposteoblast for describing phenotypic spectrum of MAT. Manipulating with MAT activity in diseases where impairment in energy metabolism correlates with bone functional deficit, such as aging and diabetes, may be beneficial for both. Paracrine activities of MAT might be considered for treatment of bone diseases. MAT has unrecognized potential, either beneficial or detrimental, to regulate bone homeostasis in physiological and pathological conditions. More research is required to harness this potential for therapeutic purposes.
Entities:
Keywords:
Beige fat; Energy metabolism; Gene markers; Marrow adipocytes; Osteoporosis
Authors: Ioanna Mosialou; Steven Shikhel; Jian-Min Liu; Antonio Maurizi; Na Luo; Zhenyan He; Yiru Huang; Haihong Zong; Richard A Friedman; Jonathan Barasch; Patricia Lanzano; Liyong Deng; Rudolph L Leibel; Mishaela Rubin; Thomas Nickolas; Wendy Chung; Lori M Zeltser; Kevin W Williams; Jeffrey E Pessin; Stavroula Kousteni Journal: Nature Date: 2017-03-08 Impact factor: 49.962
Authors: Yi Fan; Jun-Ichi Hanai; Phuong T Le; Ruiye Bi; David Maridas; Victoria DeMambro; Carolina A Figueroa; Serkan Kir; Xuedong Zhou; Michael Mannstadt; Roland Baron; Roderick T Bronson; Mark C Horowitz; Joy Y Wu; John P Bilezikian; David W Dempster; Clifford J Rosen; Beate Lanske Journal: Cell Metab Date: 2017-02-02 Impact factor: 27.287
Authors: Eliezer Calo; Jose A Quintero-Estades; Paul S Danielian; Simona Nedelcu; Seth D Berman; Jacqueline A Lees Journal: Nature Date: 2010-08-04 Impact factor: 49.962
Authors: Ulrike I Mödder; David G Monroe; Daniel G Fraser; Thomas C Spelsberg; Clifford J Rosen; Martine Géhin; Pierre Chambon; Bert W O'Malley; Sundeep Khosla Journal: J Biol Chem Date: 2009-05-07 Impact factor: 5.157
Authors: Marco Raffaele; Ignazio Barbagallo; Maria Licari; Giuseppe Carota; Giuseppe Sferrazzo; Mariarita Spampinato; Valeria Sorrenti; Luca Vanella Journal: Evid Based Complement Alternat Med Date: 2018-10-17 Impact factor: 2.629